Privia Health Group (PRVA) Company Report

Privia Health reported strong Q3 2025 results, with Adjusted EBITDA increasing 61.6% to $38.2 million and practice collections growing 27.1% to $940.4 million.
The company raised its 2025 outlook, with midpoint guidance expecting Adjusted EBITDA growth of 32% and implemented providers to reach 5,325 by year-end.
Privia Health agreed to acquire an ACO business from Elevance Health for $100 million in cash, which is expected to add over 120,000 value-based care attributed lives and positively contribute to adjusted EBITDA in 2026.
For 2024, the company achieved strong Medicare Shared Savings Program (MSSP) results, with total shared savings of $234.1 million, a 32.6% increase from the prior year.

Nov 6, 2025, 1:00 PM

Transcript

Privia Health Reports Strong Q3 2025 Results, Raises 2025 Outlook, and Announces ACO Acquisition

PRVA

Earnings

Guidance Update

M&A

Privia Health reported strong Q3 2025 results, with practice collections increasing 27.1% year-over-year to $940.4 million and Adjusted EBITDA growing 61.6% to $38.2 million, representing 30.5% of care margin.
The company raised its 2025 outlook, projecting 11.2% year-over-year growth in implemented providers to 5,325 by year-end and 32% Adjusted EBITDA growth at the midpoint.
Privia Health agreed to acquire an ACO business from Elevance Health for $100 million in cash, which is expected to add over 120,000 value-based care attributed lives and contribute positively to adjusted EBITDA in 2026.
For the 2024 Medicare Shared Savings Program (MSSP), Privia managed over $2.5 billion in medical spend, achieving an aggregate savings rate of 9.4% and gross shared savings of $160.1 million.
The company ended Q3 2025 with a strong financial position, reporting pro forma cash of $409.9 million and no debt.

Nov 6, 2025, 1:00 PM

Transcript

Privia Health Reports Strong Q3 2025 Results, Raises Full-Year Guidance, and Announces ACO Acquisition

PRVA

Earnings

Guidance Update

M&A

Privia Health reported strong Q3 2025 financial results, with practice collections increasing 27.1% year-over-year to $940.4 million and Adjusted EBITDA growing 61.6% to $38.2 million.
The company raised its 2025 outlook, with expected Adjusted EBITDA growth of 32% at the midpoint, and anticipates ending the year with at least $410 million in cash.
Privia Health agreed to acquire an ACO business from Elevance Health for $100 million in cash, which is expected to add over 120,000 value-based care attributed lives and positively contribute to adjusted EBITDA in 2026.
Operational growth continued with implemented providers reaching 5,250 at September 30, an increase of 13.1% year-over-year.

Nov 6, 2025, 1:00 PM

Transcript

PRVA Reports Strong Q3 2025 Results and Raises Full-Year Guidance

PRVA

Earnings

Guidance Update

M&A

Privia Health reported a strong third quarter 2025, with Practice Collections growing 27.1% to $940.4 million and Adjusted EBITDA increasing 61.6% to $38.2 million compared to Q3 2024.
The company raised its full-year 2025 guidance for all operating and financial metrics, with updated Adjusted EBITDA guidance ranging from $118 million to $121 million and Practice Collections from $3,450 million to $3,500 million.
As of September 30, 2025, Privia Health maintained a strong balance sheet with $409.9 million in pro forma net cash and no debt, and expects to close the acquisition of Evolent's ACO business by year-end 2025, utilizing $100 million for the transaction.
Implemented Providers grew to 5,250 in Q3 2025, a 13.1% increase compared to Q3 2024, and Attributed Lives reached 1.4 million.

Nov 6, 2025, 1:00 PM

Presentation

Privia Health Reports Strong Q3 2025 Results, Raises FY25 Guidance, and Announces ACO Acquisition

PRVA

Earnings

Guidance Update

M&A

Privia Health reported strong third quarter 2025 financial results, with total revenue increasing 32.5% to $580.4 million and Adjusted EBITDA growing 61.6% to $38.2 million compared to the prior year period.
Operational metrics also showed significant growth, with Implemented Providers reaching 5,250 (+13.1%) and Practice Collections at $940.4 million (+27.1%) for Q3 2025, leading the company to raise its full-year 2025 guidance for all key operating and financial metrics.
The company signed a definitive agreement on September 23, 2025, to acquire an ACO business from Evolent Health, Inc., which will add over 120,000 attributed lives and is expected to close in Q4 2025, while maintaining a strong balance sheet with $441.4 million in cash and cash equivalents and no debt as of September 30, 2025.

Nov 6, 2025, 11:09 AM

8-K

Privia Health Group Reports Strong Q3 2025 Results and Raises Full-Year Guidance

PRVA

Earnings

Guidance Update

M&A

Privia Health Group reported strong third-quarter 2025 financial results, with total revenue increasing 32.5% to $580.4 million and Adjusted EBITDA growing 61.6% to $38.2 million compared to Q3 2024.
Operational highlights for Q3 2025 include a 13.1% increase in Implemented Providers and a 27.1% rise in Practice Collections to $940.4 million compared to the prior year.
The company raised its full-year 2025 guidance for all key operating and financial metrics, with updated GAAP Revenue projected between $2,050 million and $2,100 million and Adjusted EBITDA between $118 million and $121 million.
On September 23, 2025, Privia Health signed an agreement to acquire an ACO business from Evolent Health, Inc., which is expected to add over 120,000 attributed lives and increase total value-based care attributed lives to over 1.5 million.

Nov 6, 2025, 11:00 AM

Press Release

Privia Health Group, Inc. to Acquire Evolent Health's ACO Business

PRVA

M&A

New Projects/Investments

Privia Health Group, Inc. (PRVA) announced on September 23, 2025, a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc..
The acquisition involves a payment of $100 million in cash at closing and up to an additional $13 million subject to final 2025 Medicare Shared Savings Program (MSSP) performance.
The acquired ACO business cares for over 120,000 attributed lives, which will increase Privia Health's total value-based care attributed lives to approximately 1.5 million.
The transaction is expected to close in the fourth quarter of 2025 and is anticipated to positively contribute to Adjusted EBITDA in 2026.

Sep 23, 2025, 8:12 PM

8-K

Privia Health Group Reports Strong Q2 2025 Results and Raises Full-Year Guidance

PRVA

Earnings

Guidance Update

Revenue Acceleration/Inflection

Privia Health Group reported strong financial performance for Q2 2025, with practice collections increasing 18.5% from Q2 2024 to $862.9 million, and Adjusted EBITDA growing 31.6% to $29 million.
For the first half of 2025, practice collections increased 15.7% to $1.66 billion, and Adjusted EBITDA grew 33.3% to $55.9 million.
The company raised its full-year 2025 guidance for practice collections, GAAP revenue, platform contribution, and Adjusted EBITDA to above the high end of initial ranges, citing strong first-half performance and implemented provider growth.
Privia Health Group ended Q2 2025 with over $390 million in cash and no debt, and anticipates continued strong performance, targeting 20% EBITDA growth into 2026.

Aug 7, 2025, 11:50 PM

Privia Health Group Q1 2025 Results & Strategic Expansion

PRVA

Earnings

M&A

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Financial Performance: Q1 2025 revenue hit $480.1 million (+15.6% YoY), with adjusted EBITDA up 35.1% and margins improved (460bps increase to 25.6%) .
Guidance Update: Raised full-year 2025 outlook to the mid- to high-end range for key metrics including GAAP revenue, practice collections, and EBITDA .
Operational Metrics: Implemented providers grew to 4,871 (+11.7%) and practice collections reached $798.6 million (+12.8%) .
Market Expansion: Completed an IMS acquisition in Arizona via a $95 million cash transaction, adding 28,000 attributed lives and positioning the market for EBITDA positivity by Q4 2025 .

May 8, 2025, 12:01 PM

Transcript Presentation 8-K

Privia Health Q4 2024 Financial Results & FY Guidance

PRVA

Earnings

Guidance Update

Revenue Acceleration/Inflection

FY 2024 Revenue & Performance: Recorded revenue of $1,736.4M with all operating and financial metrics exceeding high-end guidance .
Strong Q4 Results: Delivered a record $109.3M in free cash flow, improved gross profit, and practice collections rising to $792.5M .
Provider Growth: Implemented Providers increased by 11.2% YoY to 4,789 .
Adjusted EBITDA Expansion: Q4 performance included $24.9M in adjusted EBITDA and fee-for-service adjusted EBITDA of $90.5M, achieving a FY adjusted EBITDA margin of 22.4% .
Robust Financial Position: Ended the year with approximately $491M in cash and no debt .
2025 Guidance: Forecasts include further provider growth (projected increase to 5,250 or 9.6%) and targeted EBITDA growth of about 19%, supporting margin expansion despite market challenges .

Feb 27, 2025, 12:00 AM

Transcript Presentation 8-K

Earnings Transcripts

Quarterly earnings call transcripts for Privia Health Group.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Parth Mehrotra say about margins?What are Privia Health Group's strategic priorities?How is Privia Health Group positioned vs competitors?How did Privia Health Group do last quarter?

Let Fintool AI Agent track Privia Health Group's earnings for you

Get instant analysis when filings drop